CX11: Corxel's Oral Small-Molecule GLP-1 Posts 11.5% Weight Loss - and a Surprisingly Low Vomiting Rate (July 15, 2026)
Table of Contents
A new name in the oral GLP-1 race
The obesity-drug story of the past two years has quietly shifted from injections to pills. Semaglutide and tirzepatide proved that incretin biology can drive double-digit weight loss, but both are peptides that must be injected and cold-stored - expensive to make and inconvenient to take. The next frontier is the oral small molecule: a non-peptide that hits the same GLP-1 receptor but can be pressed into a room-temperature tablet and manufactured at the scale of an ordinary generic. Orforglipron, danuglipron, aleniglipron, ecnoglutide, and conveglipron are all chasing that prize. On June 23, 2026, a less familiar name joined the leaderboard: CX11, an oral small-molecule GLP-1 receptor agonist from Corxel Pharmaceuticals, which reported positive top-line results from its U.S. Phase 2 obesity trial.
What CX11 is - and where it came from
CX11 is an investigational once-daily oral GLP-1 receptor agonist for obesity, overweight, and type 2 diabetes. It was discovered by Vincentage Pharma in China; Corxel Pharmaceuticals acquired the global ex-China rights in December 2024 and is running the international program. Like the other entrants in this class, CX11 is a non-peptide small molecule - the design choice that unlocks oral dosing without the absorption enhancers and strict fasting windows that constrain peptide-based oral drugs such as oral semaglutide. Corxel frames CX11 as part of a broader cardiometabolic pipeline that also includes CX12, an internally discovered oral amylin receptor agonist still in preclinical work, and JX10, a thrombolytic for acute ischemic stroke.
The Phase 2 numbers
The U.S. Phase 2 trial (NCT07011797) enrolled 246 adults with obesity (BMI of 30 or higher) or overweight (BMI 27 to under 30 with at least one weight-related condition). Participants were randomized evenly to one of four CX11 arms - 120 mg, 160 mg, 200 mg with slow titration, or 200 mg with fast titration - or placebo, taken once daily for 36 weeks. CX11 met its primary endpoints, delivering up to 11.5% weight loss at 36 weeks. Notably, the weight-loss curve was still descending at the end of the study, with no evidence of a plateau - the same 'not done yet' signal that has made analysts optimistic about several drugs in this class, and a hint that longer dosing could push the number higher.
The real headline: tolerability and a clean liver
On raw weight loss, 11.5% at 36 weeks sits below aleniglipron's 16% at 44 weeks and in the same neighborhood as orforglipron's Phase 3 results - respectable but not class-leading. Where CX11 tried to differentiate was tolerability. Nausea landed at 33-34%, roughly typical for the class, but vomiting came in at just 12-16%, with no severe GI events reported and only a 5.0% discontinuation rate due to GI adverse events. Most GI complaints clustered during dose escalation and faded during maintenance. Just as important for this particular class, no hepatic safety signal was seen - across more than 1,500 participants studied to date. That detail carries weight: liver toxicity is exactly what forced Pfizer to drop its first oral GLP-1 candidate, lotiglipron, and complicated the twice-daily formulation of danuglipron. A clean liver profile is table stakes for any oral GLP-1 hoping to reach the market.
How it stacks up in a crowded field
CX11's pitch is not 'most weight lost' but 'best-tolerated at a competitive weight loss' - a positioning that matters more than it sounds, because real-world adherence to GLP-1 drugs is poor and GI side effects are a leading reason people quit. If a pill can deliver low-double-digit weight loss with less vomiting and no liver worries, it could win share on tolerability alone, especially in the overweight and mild-obesity segments where patients are less willing to tolerate misery for results. It also has an unusual regulatory footprint: partner Vincentage has already reported positive Phase 3 obesity data in China, so CX11 arrives at the global stage with more late-stage human data behind it than a typical Phase 2 asset. Cross-trial comparisons come with heavy caveats - different populations, endpoints, and titration schemes - but the direction is clear enough that Corxel is moving to pivotal global Phase 3 studies.
What to watch next
The near-term questions are practical. Full peer-reviewed data will show whether the 11.5% figure holds up across the dose arms and how the fast- versus slow-titration schedules trade off speed against tolerability. The China Phase 3 dataset, once published in detail, will help calibrate expectations for the global program. And the competitive clock matters: orforglipron is already at the FDA's door, aleniglipron heads into Phase 3 this quarter, and oral semaglutide is expanding - so CX11's global Phase 3 will have to distinguish itself in a market that is filling fast. For now, CX11 is a reminder that the oral GLP-1 race is no longer a two- or three-horse contest, and that tolerability, not just peak weight loss, may decide the winners. As always, CX11 is investigational, not approved for any use, and nothing here is medical advice.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Corxel Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Trial of CX11 in Obese and Overweight U.S. Adults - BioSpace (June 23, 2026) Source
- [2] Corxel to advance oral obesity drug to Phase III trials - Clinical Trials Arena (2026) Source
- [3] CX11 Shows Weight Loss in Phase 2 Obesity Trial, Corxel Reports - HCPLive (2026) Source
- [4] Corxel gears up for global pivotal push after oral GLP-1 posts 'competitive' phase 2 results - Fierce Biotech (2026) Source
Related Articles
The close of ADA 2026 triggered a cluster of significant developments: Structure Therapeutics published the aleniglipron ACCESS Phase 2b results in Nature Medicine on June 5 — the first peer-reviewed full-data paper for an oral non-peptide GLP-1 RA in a major journal. Novo Nordisk announced that oral semaglutide (Wegovy pill) has surpassed 3 million prescriptions in five months. CVS Caremark announced a formulary reset that places Foundayo (orforglipron) and Zepbound on equal footing with Wegovy, reshaping the commercial GLP-1 landscape. And the FDA's Pharmacy Compounding Advisory Committee will meet July 23–24, 2026 to vote on whether BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and DSIP can be legally compounded — a pivotal regulatory moment for research peptides.
The Oral GLP-1 Pill Race Widens: Conveglipron (HDM1002) Joins Orforglipron in the Hunt for a Needle-Free Weight-Loss Drug — June 15, 2026
Conveglipron (HDM1002) is an oral, once-daily small-molecule GLP-1 receptor agonist from Huadong Medicine now in Phase 2 for obesity and Phase 3 for type 2 diabetes. Here's how the GLP-1 'pill' race is shaping up against orforglipron and danuglipron — and why an oral small molecule is not the same thing as a peptide.